CA2079813A1 - Method of treatment with hsp70 - Google Patents

Method of treatment with hsp70

Info

Publication number
CA2079813A1
CA2079813A1 CA002079813A CA2079813A CA2079813A1 CA 2079813 A1 CA2079813 A1 CA 2079813A1 CA 002079813 A CA002079813 A CA 002079813A CA 2079813 A CA2079813 A CA 2079813A CA 2079813 A1 CA2079813 A1 CA 2079813A1
Authority
CA
Canada
Prior art keywords
hsp70
cell
tissue
cells
combating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002079813A
Other languages
English (en)
French (fr)
Inventor
Paul A. Berberian
Michael Tytell
David J. Gower
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wake Forest University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2079813A1 publication Critical patent/CA2079813A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002079813A 1990-04-06 1991-04-05 Method of treatment with hsp70 Abandoned CA2079813A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50593490A 1990-04-06 1990-04-06
US505,934 1990-04-06

Publications (1)

Publication Number Publication Date
CA2079813A1 true CA2079813A1 (en) 1991-10-07

Family

ID=24012485

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002079813A Abandoned CA2079813A1 (en) 1990-04-06 1991-04-05 Method of treatment with hsp70

Country Status (5)

Country Link
EP (1) EP0527783A4 (ja)
JP (1) JPH05507908A (ja)
AU (1) AU659085B2 (ja)
CA (1) CA2079813A1 (ja)
WO (1) WO1991015219A1 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5847007A (en) * 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
ES2246566T5 (es) 1998-03-27 2010-10-26 Gabriele Prof. Dr. Multhoff Aplicacion de proteinas hsp70.
US6812205B2 (en) * 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
CA2458574A1 (en) 2001-08-23 2003-03-06 Arizona Board Of Regents Reagents and methods for smooth muscle therapies
DE60335549D1 (de) * 2003-11-12 2011-02-10 Alfa Biogene Internat B V Gewinnung von Hitzeschockproteinen
CN101801402B (zh) 2007-07-06 2013-08-28 乌得勒支大学控股有限公司 炎性疾病和自身免疫疾病的治疗和预防

Also Published As

Publication number Publication date
WO1991015219A1 (en) 1991-10-17
AU659085B2 (en) 1995-05-11
JPH05507908A (ja) 1993-11-11
EP0527783A4 (en) 1993-09-01
EP0527783A1 (en) 1993-02-24
AU7677391A (en) 1991-10-30

Similar Documents

Publication Publication Date Title
US5348945A (en) Method of treatment with hsp70
US5863904A (en) Methods for treating cancers and restenosis with P21
Park et al. The gubernaculum shows rhythmic contractility and active movement during testicular descent
CN101316602A (zh) 羊膜制品和纯化的组合物及其使用方法
JP4307561B2 (ja) 創傷の治癒
JP2003530320A (ja) 甲状腺疾患の治療法
AU2703400A (en) Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application
CN110724203B (zh) 一种促进tfeb核转位的短肽及基于其的线性短肽和其减轻脑缺血损伤的应用
GB2208602A (en) Dried earthworm powder
RU2573943C2 (ru) Применение prdx2 и/или prdx6 для получения фармацевтической композиции для лечения или предотвращения повреждения, старения или заболевания, вызванных повышением уровня активных форм кислорода
CA2079813A1 (en) Method of treatment with hsp70
HU214977B (hu) Eljárás polipeptidek előállítására bakteriális gazdasejtekben javított tulajdonságú, lambda PL-promotort tartalmazó vektorok alkalmazásával
JP2002316929A (ja) Ｌ−セリン又はグリシンからなる抗アポトーシス剤
JP3980088B2 (ja) 傷治癒を改善するプラスミノーゲン活性化因子からなる製剤の使用
US8003345B2 (en) Antioxidant pharmaceutical compound, method for producing polypeptide and method of cure
CN103417961B (zh) Prdx2和/或prdx6的新用途
RU2280448C2 (ru) Композиция с антиоксидантными свойствами и способ лечения болезней млекопитающих
SCHILTZ et al. Corticosteroids, aurothioglucose and soybean trypsin inhibitor do not prevent pemphigus antibody‐induced acantholysis in vitro
RU2104704C1 (ru) Фармакологически активная субстанция защитного соединения организма 3со, способ ее получения и терапевтическое применение
AU677379B2 (en) Arteriosclerosis remedy
SNELL Vitamin K: Its Properties, Distribution and Clinical Importance: A Preliminary Report
EP3741366A1 (en) Composition comprising dunnione as effective ingredient for prevention or alleviation of hair loss
US5118624A (en) Method for the stimulation of cell growth and the inhibition of cell proliferation by the utilization of selenodithiols such as selenodiglutathione
CN111494604B (zh) 蓝藻抗病毒蛋白n在制备抗炎药物中的应用
Choi et al. Effects of small molecular antioxidants on cerulein-induced acute pancreatitis in rat

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead